C4 Therapeutics, Inc. (CCCC)
3.81
+0.10
(+2.70%)
USD |
NASDAQ |
Sep 01, 12:06
C4 Therapeutics Cash from Investing (Quarterly) : -14.82M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.82M |
| March 31, 2026 | 16.15M |
| December 31, 2025 | -80.73M |
| September 30, 2025 | 4.086M |
| June 30, 2025 | 38.92M |
| March 31, 2025 | 29.12M |
| December 31, 2024 | 13.67M |
| September 30, 2024 | 0.162M |
| June 30, 2024 | -11.71M |
| March 31, 2024 | -53.40M |
| December 31, 2023 | 31.94M |
| September 30, 2023 | 57.72M |
| June 30, 2023 | 15.15M |
| March 31, 2023 | 53.53M |
| Date | Value |
|---|---|
| December 31, 2022 | 9.284M |
| September 30, 2022 | 19.91M |
| June 30, 2022 | 33.23M |
| March 31, 2022 | -4.004M |
| December 31, 2021 | -59.41M |
| September 30, 2021 | -100.63M |
| June 30, 2021 | 32.43M |
| March 31, 2021 | -61.73M |
| December 31, 2020 | -54.22M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -0.184M |
| December 31, 2019 | -0.198M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | -9.875M |
| Rallybio Corp. | 5.50M |
| Q32 Bio, Inc. | 0.00 |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.574M |
| Cash from Financing (Quarterly) | 33.72M |
| Free Cash Flow | -85.39M |
| Free Cash Flow Per Share (Quarterly) | -0.0123 |
| Free Cash Flow to Equity (Quarterly) | -0.022M |
| Free Cash Flow to Firm (Quarterly) | -1.611M |
| Free Cash Flow Yield | -20.10% |